VCU Health doctors first in Virginia to administer newly approved ALS treatment
Tuesday, Aug. 22, 2017
On Wednesday, three VCU Health patients will be the first in Virginia to receive a newly approved medication intended to treat Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis or ALS. Radicava is an ALS-slowing medication that was recently approved by the Food and Drug Administration. The drug was first administered to U.S. patients on Aug. 11 at a medical center near Buffalo, New York. It is the first new ALS-related drug to be available in the U.S. in more than 20 years.
“VCU has worked diligently to ensure this new medication will be available to our ALS patients throughout the commonwealth,” said Scott A. Vota, D.O., director of the Neuromuscular and ALS clinics at Virginia Commonwealth University.
ALS is a rare disease that attacks and kills the nerve cells that control voluntary muscles. The nerves lose the ability to activate specific muscles, which causes the muscles to become weak and leads to paralysis. ALS is progressive, meaning it gets worse over time. The Centers for Disease Control and Prevention estimates that approximately 12,000 to 15,000 Americans have ALS. Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear.
Radicava is an intravenous infusion administered by a health care professional. The newly approved drug has been shown to slow decline of physical function by 33 percent and reduce stress in the body. It can be prescribed at any point of the disease.
“This breakthrough, albeit promising, encourages ALS centers like VCU to continue to work collaboratively until a cure is found,” Vota said.
|WHAT: First Radicava infusion in Virginia
|WHEN: Wednesday, Aug. 23, noon
Media are asked to arrive by 11:30 a.m. to set up
|WHERE: VCU Medical Center
|WHO: Neuromuscular and ALS clinics at VCU patients and families
Neuromuscular and ALS clinics at VCU team members
Media are asked to RSVP by 10 a.m. on Aug. 23
About VCU and VCU Health
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 30,000 students in 233 degree and certificate programs in the arts, sciences and humanities. Twenty-two of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 11 schools and three colleges. The VCU Health brand represents the VCU health sciences academic programs, the VCU Massey Cancer Center and the VCU Health System, which comprises VCU Medical Center (the only academic medical center in the region), Community Memorial Hospital, Tappahannock Hospital, Children’s Hospital of Richmond at VCU, and MCV Physicians. The clinical enterprise includes a collaboration with Sheltering Arms Institute for physical rehabilitation services. For more, please visit www.vcu.edu and vcuhealth.org.